Figure 2From: Heterogeneity of intratumoral 111In-ibritumomab tiuxetan and 18F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma Correlation between pretherapeutic FDG SUVmax and 111 In-ibritumomab tiuxetan SUVmax in all lesions. The solid line is the progression line. Dotted lines represent 95% confidence intervals of the progression line.Back to article page